CDx: more partnerships ahead, but more pharma awareness needed
This article was originally published in Scrip
Arguably the most significant catalyst for the greater adoption of personalised medicine came in July 2011 when the US FDA issued its draft guidance on companion diagnostics (scripintelligence.com, 18 July 2011). It didn’t do the whole job, in that it still leaves questions open about how to design and conduct clinical trials. But it did provide a clear signal that the pharma industry should continue moving towards adopting a bigger role for diagnostics as its business model evolves.
You may also be interested in...
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.